Comparison tool

Veslugen vs Livagen side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

VeslugenLivagen

Share this peptide comparison

Property	Veslugen	Livagen
Category	Bioregulators	Bioregulators
Also known as	Vesugen, KED	Lys-Glu-Asp-Ala, KEDA
FDA approved	No	No
Clinical status	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Circulatory health, vascular support, aging	Gene expression, cellular aging, liver health
How it works	Veslugen/KED is proposed to act through gene-regulatory effects rather than a conventional receptor target. The cited source describes a hypothesis in which the short peptide enters cells, localizes near nuclear DNA, and changes promoter activity linked to vascular biology. Reported mechanistic work includes molecular docking near MKI67 and experimental observations involving endothelial markers such as endothelin-1, connexins, sirtuin-1, and nitric oxide. The evidence described is largely computational, in vitro, animal-based, and concentrated within one research lineage.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typical dosing	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typical duration	10-30 day cycles	10-30 day cycles
Administration	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Evidence level	Preclinical	Preclinical
Possible side effects	Generally well tolerated (Reported by the source, but formal safety data are limited.) Limited safety data outside Russia (The source notes limited external safety evidence beyond the Russian context.) Not FDA approved (This is a regulatory limitation rather than a physiological adverse effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Research summary	The source describes KED as a defined ultrashort peptide discussed in peer-reviewed Khavinson-related literature, including review material that mentions vascular and blood-brain-barrier biology in cell and animal contexts. Reported findings include gene-expression changes, nitric oxide stimulation, and normalization of endothelial markers, but the source characterizes the evidence as mostly in vitro, molecular docking, and aged-animal work. Human evidence is described as very limited and not based on rigorous placebo-controlled trials, with little independent replication outside the originating research group.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
References	Peptibase peptides Peptibase peptides +2 more Peptibase peptides Peptibase peptides	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Veslugen

Livagen

Category

Bioregulators

Also known as

Vesugen, KED

Lys-Glu-Asp-Ala, KEDA

FDA approved

Clinical status

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Circulatory health, vascular support, aging

Gene expression, cellular aging, liver health

How it works

Veslugen/KED is proposed to act through gene-regulatory effects rather than a conventional receptor target. The cited source describes a hypothesis in which the short peptide enters cells, localizes near nuclear DNA, and changes promoter activity linked to vascular biology. Reported mechanistic work includes molecular docking near MKI67 and experimental observations involving endothelial markers such as endothelin-1, connexins, sirtuin-1, and nitric oxide. The evidence described is largely computational, in vitro, animal-based, and concentrated within one research lineage.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typical dosing

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typical duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Evidence level

Preclinical

Possible side effects

Generally well tolerated (Reported by the source, but formal safety data are limited.)
Limited safety data outside Russia (The source notes limited external safety evidence beyond the Russian context.)
Not FDA approved (This is a regulatory limitation rather than a physiological adverse effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Research summary

The source describes KED as a defined ultrashort peptide discussed in peer-reviewed Khavinson-related literature, including review material that mentions vascular and blood-brain-barrier biology in cell and animal contexts. Reported findings include gene-expression changes, nitric oxide stimulation, and normalization of endothelial markers, but the source characterizes the evidence as mostly in vitro, molecular docking, and aged-animal work. Human evidence is described as very limited and not based on rigorous placebo-controlled trials, with little independent replication outside the originating research group.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

References

Peptibase peptides Peptibase peptides

+2 more

Peptibase peptides Peptibase peptides

Source Source

+2 more

Source Source

Full profile

View Details